BMS to acquire Mirati and its cancer treatments for $5.8bn

BMS said Mirati Therapeutics is working on multiple cancer treatments and aims to add these products to its oncology portfolio.

Related Keywords

Bristol Myers Squibb ,Charles Baum ,Giovanni Caforio ,Drug Administration ,Mirati Therapeutics ,Myers Squibb ,Turning Point Therapeutics ,